Reply to: “Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors” - 14/03/15
Doi : 10.1016/j.jaad.2014.08.056
Sean D. Doherty, MD a, Abby S. Van Voorhees, MD b, Mark G. Lebwohl, MD c, Neil J. Korman, MD, PhD d, Sylvia Hsu, MD e, ⁎ 
a The Permanente Medical Group, Kaiser Permanente, Roseville, California
b University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
c Mt Sinai School of Medicine, New York, New York
d Case Western Reserve University School of Medicine, Cleveland, Ohio
e Baylor College of Medicine, Houston, Texas
∗Correspondence to: Sylvia Hsu, MD, Baylor College of Medicine, 1977 Butler Blvd, Suite E6.200, Houston, TX 77030
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Disclosure: Dr Van Voorhees served on the advisory board and was an investigator, speaker, and consultant for Amgen, receiving grants and honoraria; was an investigator, advisory board member, and speaker for Abbvie, receiving honoraria; and was an advisory board member and speaker for Janssen, receiving honoraria. She sits on the advisory board for Celgene, LEO Pharma, Pfizer, and Novartis, receiving honoraria. She also receives other monies from Merck (ex-spouse pension). Dr Lebwohl serves as a consultant for Abbott, Anacor Pharmaceuticals Inc, BioLineRX Ltd, Coronado Biosciences, Dermipsor, Galderma, Maruho Co Ltd, Novartis, Pfizer, and Valeant, for which he received honoraria and other compensation. In his role as consultant and investigator for Amgen, Celgene, Eli Lilly & Co, Janssen Ortho Biotech, and LEO Pharma, he receives grants and honoraria. GlaxoSmithKline-Stiefel provides Dr Lebwohl with honoraria for his work as an investigator and he receives grants and honoraria from Ranbaxy as an investigator. Dr Lebwohl serves as principal investigator for Can-Fite Biopharma Ltd and Centocor. Dr Korman served on the advisory board and was investigator for Celgene, Eli Lilly, and Pfizer, for which he received honoraria and grants. He has served on the advisory board for Novartis, where he received honoraria. For Janssen he has served as advisor, investigator, and speaker, receiving grants, funding, and honoraria. He served Abbott and Amgen as investigator and speaker, and as a member of the advisory board for Amgen, receiving grants and honoraria. Genentech and Astellas host him as a speaker and advisor. He has served as an investigator for Genentech and a consultant for Astellas, receiving grants and honoraria; and as a speaker for Genentech and Astellas, receiving grants and honoraria. Dr Hsu served on the advisory board for Abbott, Abbvie, Amgen, Biogen, Centocor, Dermik, Genentech, Janssen, Medicis, and Novartis, for which she received honoraria. She has been an investigator for Amgen, Centocor, Galderma, Novartis, 3M Pharmaceuticals, and PharmaDerm, for which her department received funding. Dr Doherty has no conflicts of interest to declare. |
© 2014
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 72 - N° 4
P. 744 - avril 2015 Retour au numéro
Article précédent
- Reply to: “Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors”
- Lisa Chirch, Kevin Dieckhaus, Jane M. Grant-Kels
- Surgical margins for melanoma in situ: When 5-mm margins are really 9 mm
- Joy H. Kunishige, David G. Brodland, John A. Zitelli
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?